| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3287 |
| Trial ID | NCT05665062 |
| Disease | Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Follicular Lymphoma | B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Mantle Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | SYNCAR-001 |
| Co-treatment | STK-009 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies |
| Year | 2022 |
| Country | United States |
| Company sponsor | Synthekine |
| Other ID(s) | STK-009-101 |
| Cohort 1 | |||||||||||
|
|||||||||||